TRANSFORM™Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent
EDWARDS INTUITY valve
Aortic Valve Disease+4
+ Cardiovascular Diseases
+ Heart Diseases
Treatment Study
Summary
Study start date: September 26, 2012
Actual date on which the first participant was enrolled.This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be enrolled at up to 35 centers in the US. After replacement of their aortic heart valve with the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the following intervals: discharge, 3 months, 1 year, and annually thereafter for a minimum of five years.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.934 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Inclusion Criteria - Subjects will be required to meet all inclusion criteria: Male or female, age 18 years or older Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a planned replacement as indicated in the preoperative evaluation Is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery Provide written informed consent Geographically stable and agrees to attend follow-up assessments until all subjects have completed 5 years of follow up Exclusion Criteria: - Exclusion Criteria - Subjects will not be eligible for trial participation if any of the following criteria are present: Pure aortic insufficiency Requires emergency surgery Previous aortic valve replacement Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ Requires multiple valve replacement/repair Requires a surgical procedure outside of the cardiac area (e.g., vascular endarterectomy, vascular bypass, tumor removal) Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months prior to the scheduled AVR surgery Myocardial infarction (MI) within thirty (30) days prior to valve replacement surgery Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or end-stage renal disease requiring chronic dialysis Hyperparathyroidism MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic attack (TIA) within 6 months (180 days) of the procedure Presence of non-cardiac disease limiting life expectancy to less than 12 months Hypertrophic obstructive cardiomyopathy (HOCM) Left ventricular ejection fraction ≤ 25% Documented history of substance (drug or alcohol) abuse within the last 5 years Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to the procedure Pregnancy, lactation, or planning to become pregnant; Currently incarcerated or unable to give voluntary informed consent Leucopenia (WBC < 3.5x 103/µL), or acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), or thrombocytopenia (platelet count < 50x 103/µL), or history of bleeding diathesis or coagulopathy History of myxomatous disease/connective tissue disorders (e.g., Marfan's Syndrome) Current or recent participation (within 6 weeks prior to surgery) in an investigational drug or device trial Intra-operative Exclusion Criteria Anatomic variances which contraindicate implant of the trial valve, such as: anomalous coronary arteries annular deformation or extensive calcification of the annulus or aortic root which cannot be removed significant calcium on the anterior mitral leaflet pronounced septal calcification position of coronary ostia relative to Model 8300ACD valve that would result in obstruction of blood flow Available devices are not suitably sized for the subject's annulus
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 29 locations
Keck Hospital of University of Southern California
Los Angeles, United StatesOpen Keck Hospital of University of Southern California in Google MapsUniversity of California Los Angeles
Los Angeles, United StatesHoag Memorial Hospital Presbyterian
Newport Beach, United StatesStanford University
Palo Alto, United States